Human Varicella zoster virus IgA (VZV-IgA) ELISA Kit | KTE62708

Human Varicella zoster virus IgA (VZV-IgA) ELISA Kit | KTE62708 | Gentaur UK, US & Europe Distribution

Application: This Human Varicella zoster virus IgA (VZV-IgA) ELISA Kit employs a two-site sandwich ELISA to quantitate VZV-IgA in samples. An antibody specific for VZV-IgA has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and anyVZV-IgA present is bound by the immobilized antibody. After removing any unbound substances, a biotin-conjugated antibody specific for VZV-IgA is added to the wells. After washing, Streptavidin conjugated Horseradish Peroxidase (HRP) is added to the wells. Following a wash to remove any unbound avidin-enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of VZV-IgA bound in the initial step. The color development is stopped and the intensity of the color is measured.

Detection Method: Colorimetric

Conjugate: N/A

Sample Type: Cell culture supernatants#Serum#Plasma#Other biological fluids

Assay Type: Multiple steps standard sandwich ELISA assay with a working time of 3-5 hours. It depends on the experience of the operation person.

Kit Component: • Human Varicella zoster virus IgA microplate
• Human Varicella zoster virus IgA standard
• Human Varicella zoster virus IgA detect antibody
• Streptavidin-HRP
• Standard diluent
• Assay buffer
• HRP substrate
• Stop solution
• Wash buffer
• Plate covers

Features & Benefits: Human Varicella zoster virus IgA (VZV-IgA) ELISA Kit has high sensitivity and excellent specificity for detection of Human VZV-IgA. No significant cross-reactivity or interference between Human VZV-IgA and analogues was observed.

Calibration Range: Please inquire

Limit Of Detection: Please inquire

Usage Note: • Do not mix components from different kit lots or use reagents beyond the kit expiration date.
• Allow all reagents to warm to room temperature for at least 30 minutes before opening.
• Pre-rinse the pipet tip with reagent, use fresh pipet tips for each sample, standard and reagent to avoid contamination.
• Unused wells must be kept desiccated at 4 °C in the sealed bag provided.
• Mix Thoroughly is very important for the result. It is recommended using low frequency oscillator or slight hand shaking every 10 minutes.
• It is recommended that all samples and standards be assayed in duplicate or triplicate.

Storage Instruction: The unopened kit should be stored at 2 - 8°C. After opening, please store refer to protocols.

Shipping: Gel pack with blue ice.

Precaution The product listed herein is for research use only and is not intended for use in human or clinical diagnosis. Suggested applications of our products are not recommendations to use our products in violation of any patent or as a license. We cannot be responsible for patent infringements or other violations that may occur with the use of this product.

Background: Varicella-Zoster Virus (human herpes virus 3, HHV-3) belongs to the a-subfamily of herpesviridae. The virus particles measure about 145 nm in diameter. They consist of doublestranded DNA, are surrounded by an icosahedral protein capsid and an envelope which contains both host cells and viral components. The virus is usually transmitted in respiratory secretions, and a single serotype causes varicella (Chickenpox), a highly infectious childhood disease, and zoster (shingles), a neurodermic disease; both diseases are found world-wide. Varicella is the acute disease which follows primary contact with the virus, whereas zoster is the response of the partially immune host to a reactivation of the varicella virus present in the body in latent form. Varicella is endemic, most commonly affected are children between 2 and 6 years of age. The course of disease is usually mild and complicated only in immunocompromised children. Rare fatal cases show multiple necrotic lesions in brain, lung (varicella pneumonia), kidneys (hemorrhagic nephritis), spleen, bone marrow, and occasionally in the intestinal tract. The lethality of varicella is below 0.1%. In the infrequent adult infections the disease is more severe, and complications are to be expected in about 5% of all cases. Zoster is of low incidence and appears with increasing frequency and severity with advancing age. Usually the process remains localized, generalization is frequently encountered in a state of immunosuppression. Fatal cases are very rare and nearly always caused by an underlying disease.

Alternative Names: VZV-IgA

Search name: VZV-IgA

Tag: VZV-IgA